A detailed history of Met Life Investment Management, LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 51,425 shares of SMMT stock, worth $918,964. This represents 0.01% of its overall portfolio holdings.

Number of Shares
51,425
Previous 51,425 -0.0%
Holding current value
$918,964
Previous $401,000 180.8%
% of portfolio
0.01%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$2.39 - $10.92 $28,424 - $129,871
-11,893 Reduced 18.78%
51,425 $401,000
Q1 2024

May 14, 2024

BUY
$2.55 - $5.07 $161,460 - $321,022
63,318 New
63,318 $262,000
Q3 2023

May 09, 2024

BUY
$1.54 - $2.42 $97,509 - $153,229
63,318 New
63,318 $118,000
Q2 2023

Apr 29, 2024

BUY
$1.32 - $2.81 $83,579 - $177,923
63,318 New
63,318 $158,000
Q2 2023

Aug 10, 2023

BUY
$1.32 - $2.81 $83,579 - $177,923
63,318 New
63,318 $158,000

Others Institutions Holding SMMT

About Summit Therapeutics Inc.


  • Ticker SMMT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 201,215,008
  • Market Cap $3.6B
  • Description
  • Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...
More about SMMT
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.